C6/Complement component C6 Protein, Human (HEK293, His)

C6/Complement component C6 Protein is a part of the lytic membrane attack complex formed during complement activation, which has an indispensable role in innate and acquired immune responses by forming pores in the plasma membrane of target cells, as well as cancer immune surveillance. It is a component of the complement cascade which can be incorporated into the cell membrane and cause cell lysis. People with C6 deficiency are prone to bacterial infection. C6/Complement component C6 Protein, Human (HEK293, His) is the recombinant human-derived C6/Complement component C6 protein, expressed by HEK293 , with C-His labeled tag.

Complement component C6 (C6) is a part of the lytic membrane attack complex formed during complement activation, which has an indispensable role in innate and acquired immune responses by forming pores in the plasma membrane of target cells, as well as cancer immune surveillance. It is a component of the complement cascade which can be incorporated into the cell membrane and cause cell lysis. Purified human C6 is unique to the terminal complement pathway and also plays a critical role in inflammatory responses. C6 deficiency is the most common terminal complement component deficiency and can present later in age with N. meningitidis infections^[1][2].

Measured by its ability to inhibit the proliferation of HepG2 cells. The ED₅₀ for this effect is 4.961 μg/mL, corresponding to a specific activity is 201.57 units/mg.

• 
  Measured by its ability to inhibit the proliferation of HepG2 cells. The ED₅₀ for this effect is 4.961 μg/mL, corresponding to a specific activity is 201.57 units/mg.

Human

HEK293

C-10*His

AAA59668 (C22-A934)

729  [NCBI]

CFCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQENFCEQICSKQETRECNWQRCPINCLLGDFGPWSDCDPCIEKQSKVRSVLRPSQFGGQPCTEPLVAFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERDCGRTKAVCTRKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVKSSRTSNPYRVPANLENVGFEVQTAEDDLKTDFYKDLTSLGHNENQQGSFSSQGGSSFSVPIFYSSKRSENINHNSAFKQAIQASHKKDSSFIRIHKVMKVLNFTTKAKDLHLSDVFLKALNHLPLEYNSALYSRIFDDFGTHYFTSGSLGGVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFAKKTKVEHRCTTNKLSEKHEGSFIQGAEKSISLIRGGRSEYGAALAWEKGSSGLEEKTFSEWLESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQCAPCPNNGRPTLSGTECLCVCQSGTYGENCEKQSPDYKSNAVDGQWGCWSSWSTCDATYKRSRTRECNNPAPQRGGKRCEGEKRQEEDCTFSIMENNGQPCINDDEEMKEVDLPEIEADSGCPQPVPPENGFIRNEKQLYLVGEDVEISCLTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQEVLTITPFQRLYRIGESIELTCPKGFVVAGPSRYTCQGNSWTPPISNSLTCEKDTLTKLKGHCQLGQKQSGSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEKCLNNQQLHFLHIGSCQDGRQLEWGLERTRLSSNSTKKESCGYDTCYDWEKCSASTSKCVCLLPPQCFKGGNQLYCVKMGSSTSEKTLNICEVGTIRCANRKMEILHPGKCLAI

Approximately 105-120 kDa due to the glycosylation.

• 
  Greater than 90% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.